Elagolix With Add-Back Rapidly Improves Nonbleeding Symptoms in Individuals With Fibroid-Associated Heavy Menstrual Bleeding [ID: 1368052]
James A. Simon(George Washington University), Brett Pinsky(AbbVie (United States)), Susan Jewell(Netherlands Institute for Radio Astronomy), Moming Li(AbbVie (United States)), Juki Ng(AbbVie (United States))
Cited by 0
Related Papers
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
|New England Journal of Medicine|2017|492
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
|The American Journal of Surgical Pathology|2009|470
A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms
|The American Journal of Surgical Pathology|2012|227
Long-Term Outcomes of Elagolix in Women With Endometriosis
|Obstetrics and Gynecology|2018|132
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
|Annals of Oncology|2013|125